TRAW

#4789
Traws Pharma, Inc. - Common Stock
0.5 6 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.56
0.56
Jahresspanne
0.43
3.25
Tagesänderung
-1.75%
Monatliche Änderung
+14.29%
6 month change
-66.27%
Jahresänderung
-65.64%
Vorheriger Schlusskurs
0.5 7
Open
0.5 6
Tief
0.5 6
Hoch
0.5 6
Volumen
1
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Traws Pharma, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K

Traws Pharma, Inc. current report, Q1 FY2022

Full document

Business Context and Reporting Period

This Form 8-K was filed by Onconova Therapeutics, Inc. (not Traws Pharma, Inc.) on February 9, 2022, reporting events occurring on February 7, 2022. The registrant is a Delaware corporation with its principal executive offices in Newtown, PA, and its common stock trades on The Nasdaq Stock Market under the symbol ONTX.

Key Financial Metrics

This filing is a current report regarding executive compensation and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.

Material Changes

The material event reported is the approval by the Compensation Committee of new equity awards for named executive officers under the 2021 Incentive Compensation Plan. The awards consist of stock options and restricted stock units (RSUs) granted to:

  • Steven M. Fruchtman, M.D. (CEO): 191,880 options and 63,960 RSUs.
  • Mark Guerin (CFO): 62,100 options and 20,700 RSUs.
  • Abraham N. Oler (SVP, Corporate Development and General Counsel): 54,050 options and 17,633 RSUs.

The awards were determined based on recommendations from the independent compensation consultant, Radford, utilizing peer group and competitive market survey data.

Guidance, Outlook, and Vesting Terms

The filing details the vesting schedules for the granted equity awards:

  • Stock Options: Vest over three years. One-third vests on the first anniversary of the grant date, with the remainder vesting in 24 equal monthly installments over the following two years.
  • RSUs: Vest over three years. 33% vests on the first anniversary, 33% on the second anniversary, and 34% on the third anniversary.

All awards are subject to the executive's continued employment through the applicable vesting dates. The filing does not provide forward-looking financial guidance, risk factors, or management commentary beyond the compensation approval.

Investor Verification Checklist

  • Verify the total number of shares authorized under the 2021 Incentive Compensation Plan to assess remaining capacity for future grants.
  • Review the fair value of the granted options and RSUs in the company's most recent 10-Q or 10-K to estimate the associated compensation expense.
  • Confirm the current stock price of ONTX to evaluate the intrinsic value of the granted options.
  • Check for any subsequent filings regarding the resignation or termination of the named executive officers, which would impact vesting.